Global Information
회사소개 | 문의 | 비교리스트

중국의 애플리버셉트(Aflibercept) 시장(2022-2031년)

Investigation Report on China´s Aflibercept Market 2022-2031

리서치사 China Research and Intelligence
발행일 2022년 07월 상품코드 1105809
페이지 정보 영문 40 Pages 배송안내 1-2일 (영업일 기준)
가격
US $ 3,200 ₩ 4,193,000 Unprintable PDF (Single User License)
US $ 4,800 ₩ 6,290,000 Printable & Editable PDF (Enterprisewide License)


중국의 애플리버셉트(Aflibercept) 시장(2022-2031년) Investigation Report on China´s Aflibercept Market 2022-2031
발행일 : 2022년 07월 페이지 정보 : 영문 40 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

2018년에 애플리버셉트가 중국 시장에 출시된 이래 중국의 애플리버셉트 판매량은 2018년에 830만 위안에 달했고, 2018-2021년간 연평균 복합 성장률(CAGR) 206%로 성장하여 2021년에는 2억 3,800만 위안에 이르렀습니다. 2021년은 COVID-19 유행에 의해 CAGR 116%로 성장이 둔화되었으나, 유행 상황이 개선되면서 2023년부터 2026년까지는 회복세로 돌아설 것으로 예측됩니다.

2022년 7월 기준으로 Bayer AG는 중국 애플리버셉트 시장의 유일한 제조업체입니다. 그러나, 중국에서는 많은 제약회사가 애플리버셉트의 제네릭화를 진행하고 있어서 향후 5년 이내에 후발 의약품이 중국 시장에 출시될 것으로 예측됩니다. 그러나, 단기적으로는 바이엘 선발 의약품에 큰 영향을 미치치는 못할 것으로 예상됩니다.

중국의 애플리버셉트(Aflibercept) 시장에 대해 조사분석했으며, 시장 규모, 제조업체 분석, 시장 예측 등의 정보를 제공합니다.

제1장 애플리버셉트 관련 개념

  • 애플리버셉트의 적응증
  • 중국의 애플리버셉트 개발
  • 중국 정부의 애플리버셉트 승인
  • 중국의 애플리버셉트 판매에 대한 COVID-19의 영향

제2장 중국의 애플리버셉트 판매(2018-2021년)

  • 애플리버셉트 매출
    • 전체 매출
    • 지역별 매출
  • 애플리버셉트 판매 수량
    • 전체 판매 수량
    • 지역별 판매 수량
  • 중국의 애플리버셉트 판매 : 투여 방법별(2018-2021년)
    • 안내 주사
    • 기타 투여 방법 분석

제3장 중국의 주요 애플리버셉트 제조업체 분석(2018-2021년)

  • 주요 애플리버셉트 제조업체의 시장 점유율 분석
    • 시장 점유율 조사 : 매출별
    • 시장 점유율 조사 : 판매 수량별
  • Bayer AG
    • 기업 개요
    • 중국에서의 EYLEA(Bayer의 애플리버셉트) 판매

제4장 중국 다양한 제조업체의 애플리버셉트 가격(2021-2022년)

  • Bayer AG(EYLEA)
  • 기타

제5장 중국의 애플리버셉트 시장 전망(2022-2031년)

  • 중국의 애플리버셉트 시장 개발 영향요인
    • 중국 애플리버셉트 시장에 대한 COVID-19의 영향
    • 시장 성장 촉진요인과 기회
    • 시장 위협과 과제
  • 시장 규모 예측
  • 시장 동향 예측
LSH 22.08.04

List of Charts

  • Chart Aflibercept Drugs Approved by Chinese Government, by 2022
  • Chart Sales Value of Aflibercept in China, 2018-2021
  • Chart Sales Value of Aflibercept in Regions of China, 2018-2021 (Unit: CNY thousand)
  • Chart Sales Volume of Aflibercept in China, 2018-2021
  • Chart Sales Volume of Aflibercept in Regions of China,2018-2021
  • Chart Sales value and volume of aflibercept intravitreal injection in China 2018-2021
  • Chart Market Share of Aflibercept Manufacturers by Sales Value in China, 2018-2021
  • Chart Market Share of Aflibercept Manufacturers by Sales Volume in China, 2018-2021
  • Chart Profile of Bayer AG
  • Chart Sales Value of Bayer AG's Aflibercept in China, 2018-2021
  • Chart Sales Volume of Bayer AG 's Aflibercept in China, 2018-2021
  • Chart EYLEA sold in the Chinese market
  • Chart Prices of BAYER AG's Aflibercept (EYLEA ®) in Parts of China, 2021
  • Chart Forecast on sales of aflibercept in China 2022-2026

Aflibercept is an anti-VEGF drug, mainly used to treat neovascular age-related macular degeneration (wAMD), and other retinopathy caused by visual impairment. Aflibercept was jointly developed by Regeneron and Bayer. Regeneron has exclusive sales rights in the U.S. market, while Bayer obtains exclusive sales rights outside the U.S. Their Aflibercept, EYLEA was launched in China in 2018. By July 2022, Bayer AG is the only manufacturer in the Chinese Aflibercept market.

According to CRI's market research, after Aflibercept entered the Chinese market, the sales value of Aflibercept in China increased from CNY8.3 million in 2018 to CNY238 million in 2021. The annual growth rate in 2021 was 116%, which slowed down due to the COVID-19 epidemic. The CAGR of sales value of aflibercept in China is 206% from 2018 to 2021.

CRI analyzes that as the epidemic situation has been improved and the hospitals resume their operation, the sales of Aflibercept will have a recovery growth from 2023 to 2026. In addition, the sales will also increase due to market expansion. Currently, China has only approved two indications for Aflibercept, including treatment of wAMD and treatment of DME. However, Aflibercept had five approved indications globally, which means the sales will continue to grow as the number of indications expands. On the other hand, though the anti-VEGF ophthalmic drug market where Aflibercept belongs to accounts for the largest market share in the ophthalmology drug industry, the penetration rate for the anti-VEGF drug is still low. The penetration rate for the anti-VEGF drug is about 1% in China, while it exceeds 5% in the U.S. Since the market demand has not yet reached saturation, the sales will keep increasing. Besides, Aflibercept was included in the national medical insurance catalog at the beginning of 2020, so the price has been lowered, which reduces the burden on patients and will stimulate sales in the future.

Qilu Pharmaceutical, a local Chinese pharmaceutical company, received CDE (CENTER FOR DRUG EVALUATION, NMPA) approval for its marketing authorization application for aflibercept intravitreal injection in April 2022, which is the first biosimilar application for aflibercept in China.

According to CRI's market research, a number of other pharmaceutical companies in China are in the process of genericizing aflibercept, such as Clover Biopharmaceuticals' aflibercept intraocular injection, which is in the clinical phase of application, and Shandong Boan Biotechnology Co.

It is expected that the generic version of aflibercept will enter the Chinese market in the next five years, but it is unlikely to have a significant impact on Bayer's original drug in the short term.

Topics covered:

  • The impact of COVID-19 on China's aflibercept market
  • Sales value and volume of China's aflibercept 2016-2020
  • Competitive landscape of China's aflibercept market
  • Prices of aflibercept in China
  • Prices of aflibercept in China by regions and manufacturers
  • Analysis on factors affecting the development of China's aflibercept market
  • Prospect of China's aflibercept market from 2021 to 2025

Table of Contents

1 Relevant Concepts of Aflibercept

  • 1.1 Indications for Aflibercept
  • 1.2 Development of Aflibercept in China
  • 1.3 Governmental Approval of Aflibercept in China
  • 1.4 The Impact of COVID-19 on Aflibercept sales in China

2 Sales of Aflibercept in China, 2018-2021

  • 2.1 Sales Value of Aflibercept
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Aflibercept
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Aflibercept by Dosage Form in China, 2018-2021
    • 2.3.1 Intraocular Injection
    • 2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Aflibercept Manufacturers in China, 2018-2021

  • 3.1 Analysis of Market Share of Major Aflibercept Manufacturers
    • 3.1.1 Investigation on Market Share by Sales Value
    • 3.1.2 Investigation on Market Share by Sales volume
  • 3.2 Bayer AG
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of EYLEA (Bayer's Aflibercept) in China

4 Prices of Aflibercept for Different Manufacturers in China, 2021-2022

  • 4.1 Bayer AG (EYLEA)
  • 4.2 Others

5 Prospect of Chinese Aflibercept drug Market, 2022-2031

  • 5.1 Influential Factors of Chinese Aflibercept Market Development
    • 5.1.1 The Impact of COVID-19 on Chinese Aflibercept Market
    • 5.1.2 Market Drivers and Opportunities
    • 5.1.3 Market Threats and Challenges
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend
Back to Top
전화 문의
F A Q